Pilot Study of Fosaprepitant (MK-0517) for Breakthrough Chemotherapy Induced Nausea and Vomiting.

Trial Profile

Pilot Study of Fosaprepitant (MK-0517) for Breakthrough Chemotherapy Induced Nausea and Vomiting.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Fosaprepitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov (NCT00939302).
    • 01 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov (NCT00939302).
    • 15 May 2012 Planned end date changed from 1 Jan 2013 to 1 Dec 2012 as reported by ClinicalTrials.gov. (NCT01031953)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top